 REDWOOD CITY, Calif.--BUSINESS WIRE--Guardant Health, Inc. Nasdaq: GH, to present data demonstrating the use of the companys proprietary blood tests to advance precision oncology, including cancer screening, detecting residual or recurrent disease in early-stage cancer, and treatment selection and treatment response monitoring in advanced cancer. Data, from 20 abstracts, will be presented along with other leading medical institutions and pharmaceutical companies, during the 2021 American S 